
Type 2 Diabetes Drug Development Program
Our primary drug development program.
Type 2 diabetes (T2D) is a chronic, metabolic disease in which blood sugar levels become elevated due to the body’s cells becoming resistant to insulin.

With over 1.3 million people living with T2D in Australia and T2D accounting for 85-90% of all diabetes cases (537 million diabetes patients globally), T2D is a global public health problem.
Global Prevalence of Diabetes in 2021

Complications associated with T2D
As high blood glucose levels over a long period of time can damage the body’s blood vessels, T2D is associated with many health complications.

Drawbacks of current medications for T2D
Current T2D treatments lower blood glucose, but do not target underlying insulin resistance. A treatment that reduces insulin resistance would lower blood glucose levels and change the underlying course of the disease.
New therapies such as Ozempic are promising but do not directly address the issue of insulin resistance.

Our Approach to Reduce Insulin Resistance for Treating T2D
ProGenis Pharmaceuticals is developing a precision, small RNA medicine to target the gene that causes insulin resistance. By improving insulin sensitivity to facilitate glucose uptake by the body’s cells, our therapy would serve as a preferred alternative to insulin therapy.
Our lead drug candidate has been tested in cellular and mouse models of T2D and has demonstrated superior effi cacy in reducing the expression of the insulin-resistance causing gene. The drug has also shown positive clinical effects, including reduced blood glucose levels and reduced insulin resistance.
